GoodRx Holdings, Inc. Peer Comparison
Metric | Value | Ranking | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $1.8 Billion | 7/18 | VEEV $37.9B |
DOCS $14.1B |
PRVA $2.9B |
CERT $2.2B |
TDOC $2.2B |
PGNY $1.9B |
GDRX $1.8B |
SDGR $1.7B |
NXGN $1.6B |
TXG $1.4B |
EVH $1.1B |
HSTM $1.0B |
TALK $675.7M |
DH $605.3M |
ACCD $563.6M |
NRC $405.0M |
HCAT $331.0M |
AMWL $189.2M |
Gross Margin | 94% | 3/18 | PRVA 100% |
HSTM 95% |
GDRX 94% |
DOCS 90% |
DH 78% |
VEEV 75% |
TDOC 72% |
TXG 70% |
CERT 61% |
NRC 53% |
SDGR 50% |
NXGN 46% |
TALK 46% |
HCAT 45% |
ACCD 44% |
AMWL 37% |
PGNY 21% |
EVH 13% |
Profit Margin | 6% | 5/18 | DOCS 32% |
VEEV 27% |
NRC 16% |
HSTM 8% |
GDRX 6% |
PGNY 4% |
NXGN 3% |
PRVA 1% |
CERT -1% |
TALK -3% |
EVH -5% |
TDOC -5% |
HCAT -19% |
TXG -24% |
AMWL -71% |
SDGR -100% |
ACCD -100% |
DH -100% |
EBITDA margin | 7% | 6/18 | DOCS 39% |
NRC 27% |
VEEV 26% |
HSTM 24% |
NXGN 11% |
GDRX 7% |
PGNY 4% |
PRVA 2% |
TALK 0% |
EVH -1% |
TDOC -7% |
CERT -7% |
HCAT -9% |
ACCD -15% |
TXG -16% |
AMWL -51% |
DH -178% |
SDGR -194% |
Quarterly Revenue | $195.3 Million | 6/18 | VEEV $699.2M |
TDOC $640.5M |
EVH $621.4M |
PRVA $437.9M |
PGNY $286.6M |
GDRX $195.3M |
NXGN $176.4M |
TXG $151.7M |
TALK $138.8M |
DOCS $136.8M |
ACCD $105.1M |
CERT $94.8M |
HCAT $76.4M |
HSTM $73.1M |
DH $62.7M |
AMWL $61.0M |
NRC $35.8M |
SDGR $35.3M |
Quarterly Earnings | $12.3 Million | 3/18 | VEEV $185.8M |
DOCS $44.2M |
GDRX $12.3M |
PGNY $10.4M |
HSTM $5.7M |
NRC $5.7M |
NXGN $5.1M |
PRVA $3.5M |
CERT -$1.4M |
TALK -$3.6M |
HCAT -$14.7M |
EVH -$31.2M |
TDOC -$33.3M |
TXG -$35.8M |
SDGR -$38.1M |
AMWL -$43.5M |
ACCD -$121.3M |
DH -$130.9M |
Quarterly Free Cash Flow | $123.6 Million | 3/18 | TDOC $168.8M |
VEEV $164.1M |
GDRX $123.6M |
DOCS $70.1M |
PGNY $42.7M |
PRVA $38.2M |
HSTM $33.6M |
CERT $25.5M |
DH $20.1M |
TXG $17.8M |
EVH $12.4M |
HCAT $12.2M |
NRC $7.8M |
TALK $4.6M |
ACCD -$7.8M |
NXGN -$19.0M |
AMWL -$24.4M |
SDGR -$34.6M |
Trailing 4 Quarters Revenue | $790.4 Million | 6/18 | VEEV $2.7B |
TDOC $2.6B |
EVH $2.5B |
PRVA $1.7B |
PGNY $1.1B |
GDRX $790.4M |
NXGN $695.1M |
TXG $629.7M |
DOCS $516.8M |
ACCD $446.7M |
CERT $372.8M |
HCAT $302.1M |
HSTM $288.0M |
TALK $272.7M |
DH $255.8M |
AMWL $254.0M |
SDGR $193.3M |
NRC $144.2M |
Trailing 4 Quarters Earnings | -$7.9 Million | 9/18 | VEEV $699.2M |
TDOC $640.5M |
EVH $621.4M |
PRVA $437.9M |
PGNY $286.6M |
GDRX $195.3M |
NXGN $176.4M |
TXG $151.7M |
TALK $138.8M |
DOCS $136.8M |
ACCD $105.1M |
CERT $94.8M |
HCAT $76.4M |
HSTM $73.1M |
DH $62.7M |
AMWL $61.0M |
NRC $35.8M |
SDGR $35.3M |
Quarterly Earnings Growth | 132% | 1/18 | GDRX 132% |
CERT 97% |
AMWL 68% |
TXG 62% |
HSTM 48% |
DOCS 44% |
TDOC 42% |
SDGR 39% |
VEEV 37% |
HCAT 33% |
DH 24% |
TALK 19% |
EVH 6% |
NRC -28% |
PGNY -34% |
PRVA -37% |
NXGN -63% |
ACCD -476% |
Annual Earnings Growth | -106% | 15/18 | TALK 63% |
DOCS 50% |
AMWL 48% |
VEEV 42% |
EVH 35% |
TXG 35% |
HCAT 34% |
HSTM 21% |
CERT 11% |
PGNY -6% |
NRC -9% |
ACCD -51% |
PRVA -53% |
DH -85% |
GDRX -106% |
NXGN -136% |
SDGR -261% |
TDOC -289% |
Quarterly Revenue Growth | 8% | 6/18 | TALK 259% |
DOCS 20% |
VEEV 13% |
NXGN 11% |
CERT 11% |
GDRX 8% |
ACCD 6% |
PRVA 5% |
HSTM 4% |
HCAT 3% |
PGNY 2% |
EVH 0% |
TXG -1% |
AMWL -1% |
TDOC -3% |
DH -4% |
NRC -6% |
SDGR -17% |
Annual Revenue Growth | 6% | 8/18 | TALK 87% |
EVH 75% |
SDGR 31% |
DOCS 18% |
ACCD 15% |
NXGN 12% |
VEEV 11% |
GDRX 6% |
TXG 6% |
HSTM 4% |
CERT 4% |
PRVA 4% |
HCAT 3% |
DH 3% |
PGNY 2% |
AMWL 2% |
TDOC -1% |
NRC -2% |
Cash On Hand | $423.8 Million | 3/18 | TDOC $1.2B |
VEEV $1.0B |
GDRX $423.8M |
PRVA $422.0M |
TXG $398.2M |
HCAT $328.3M |
AMWL $244.6M |
CERT $233.0M |
ACCD $185.9M |
DOCS $184.2M |
SDGR $160.4M |
DH $137.6M |
TALK $119.0M |
EVH $96.6M |
PGNY $91.5M |
HSTM $57.5M |
NXGN $53.9M |
NRC $3.5M |
Short Term Debt | $9.3 Million | 6/18 | TDOC $550.7M |
HCAT $233.8M |
SDGR $16.9M |
ACCD $14.7M |
TXG $9.4M |
GDRX $9.3M |
VEEV $9.2M |
NRC $8.7M |
EVH $6.2M |
AMWL $3.7M |
NXGN $3.5M |
CERT $3.0M |
PRVA $2.6M |
DH $2.5M |
DOCS $2.2M |
PGNY -$0 |
TALK -$0 |
HSTM -$27.6M |
Long Term Debt | $47.7 Million | 9/18 | TDOC $1.6B |
EVH $629.0M |
CERT $303.5M |
NXGN $270.0M |
HCAT $130.6M |
SDGR $103.3M |
TXG $76.5M |
VEEV $62.5M |
GDRX $47.7M |
NRC $44.9M |
ACCD $21.1M |
HSTM $17.9M |
PGNY $16.6M |
DOCS $11.3M |
DH $8.3M |
AMWL $5.4M |
PRVA $3.6M |
TALK $0 |
PE | -1.00 | 7/18 | PRVA 225.89 |
DOCS 81.02 |
VEEV 56.89 |
HSTM 51.27 |
PGNY 32.74 |
NRC 14.96 |
GDRX -1.00 |
EVH -1.00 |
TDOC -1.00 |
HCAT -1.00 |
NXGN -1.00 |
TXG -1.00 |
SDGR -1.00 |
ACCD -1.00 |
AMWL -1.00 |
CERT -1.00 |
DH -1.00 |
TALK -1.00 |
PS | 2.33 | 9/18 | DOCS 27.29 |
VEEV 14.26 |
SDGR 8.98 |
CERT 5.90 |
HSTM 3.51 |
NRC 2.81 |
TALK 2.48 |
DH 2.37 |
GDRX 2.33 |
NXGN 2.31 |
TXG 2.27 |
PRVA 1.69 |
PGNY 1.65 |
ACCD 1.26 |
HCAT 1.10 |
TDOC 0.83 |
AMWL 0.74 |
EVH 0.45 |
PB | 2.64 | 10/18 | DOCS 14.68 |
NRC 11.70 |
VEEV 6.89 |
TALK 5.75 |
PRVA 4.37 |
PGNY 4.31 |
SDGR 3.86 |
NXGN 3.79 |
HSTM 2.84 |
GDRX 2.64 |
CERT 2.09 |
TXG 1.98 |
ACCD 1.80 |
TDOC 1.43 |
HCAT 0.93 |
EVH 0.91 |
DH 0.87 |
AMWL 0.54 |
PC | 4.34 | 13/18 | NRC 117.01 |
DOCS 76.56 |
VEEV 36.27 |
NXGN 29.82 |
PGNY 20.50 |
HSTM 17.58 |
EVH 11.59 |
SDGR 10.83 |
CERT 9.44 |
PRVA 6.86 |
TALK 5.68 |
DH 4.40 |
GDRX 4.34 |
TXG 3.59 |
ACCD 3.03 |
TDOC 1.74 |
HCAT 1.01 |
AMWL 0.77 |
Liabilities to Equity | 0.95 | 7/18 | NRC 2.81 |
TDOC 1.34 |
HCAT 1.29 |
EVH 1.23 |
ACCD 1.07 |
NXGN 1.03 |
GDRX 0.95 |
PRVA 0.79 |
DH 0.70 |
PGNY 0.52 |
SDGR 0.49 |
CERT 0.46 |
HSTM 0.41 |
AMWL 0.39 |
TXG 0.30 |
TALK 0.18 |
VEEV 0.17 |
DOCS 0.16 |
ROA | -0.01 | 7/18 | NRC 21% | DOCS 16% | VEEV 10% | PGNY 9% | HSTM 4% | PRVA 1% | GDRX -1% | NXGN -1% | CERT -2% | EVH -4% | TALK -5% | HCAT -10% | TXG -19% | SDGR -27% | TDOC -28% | ACCD -28% | DH -31% | AMWL -44% |
ROE | -0.01 | 7/18 | NRC 78% |
DOCS 18% |
PGNY 13% |
VEEV 12% |
HSTM 6% |
PRVA 2% |
GDRX -1% |
NXGN -1% |
CERT -3% |
TALK -6% |
EVH -9% |
HCAT -22% |
TXG -25% |
SDGR -40% |
DH -52% |
ACCD -58% |
AMWL -64% |
TDOC -65% |
Current Ratio | 2.06 | 12/18 | DOCS 7.11 |
VEEV 6.78 |
TALK 6.70 |
TXG 4.36 |
AMWL 3.63 |
HSTM 3.41 |
CERT 3.15 |
SDGR 3.04 |
PGNY 2.93 |
DH 2.43 |
PRVA 2.37 |
GDRX 2.06 |
NXGN 1.97 |
EVH 1.96 |
ACCD 1.94 |
HCAT 1.78 |
TDOC 1.75 |
NRC 1.36 |
Quick Ratio | 0.64 | 11/18 | PRVA 225.89 |
DOCS 81.02 |
VEEV 56.89 |
HSTM 51.27 |
PGNY 32.74 |
NRC 14.96 |
GDRX -1.00 |
EVH -1.00 |
TDOC -1.00 |
HCAT -1.00 |
NXGN -1.00 |
TXG -1.00 |
SDGR -1.00 |
ACCD -1.00 |
AMWL -1.00 |
CERT -1.00 |
DH -1.00 |
TALK -1.00 |
Long Term Debt to Equity | 0.07 | 9/18 | NRC} 1.30 |
TDOC} 1.05 |
NXGN} 0.64 |
EVH} 0.61 |
HCAT} 0.37 |
CERT} 0.29 |
SDGR} 0.23 |
TXG} 0.11 |
GDRX} 0.07 |
ACCD} 0.07 |
HSTM} 0.05 |
PGNY} 0.04 |
AMWL} 0.02 |
VEEV} 0.01 |
PRVA} 0.01 |
DOCS} 0.01 |
DH} 0.01 |
TALK} 0.00 |
Debt to Equity | 0.08 | 10/18 | NRC 1.55 |
TDOC 1.05 |
HCAT 1.03 |
NXGN 0.65 |
EVH 0.61 |
CERT 0.29 |
SDGR 0.27 |
TXG 0.12 |
ACCD 0.09 |
GDRX 0.08 |
HSTM 0.05 |
PGNY 0.04 |
AMWL 0.03 |
DH 0.02 |
VEEV 0.01 |
PRVA 0.01 |
DOCS 0.01 |
TALK 0.00 |
Burn Rate | -52.78 | 17/18 | TALK 33.10 |
CERT 16.34 |
TXG 9.67 |
NXGN 8.14 |
AMWL 5.49 |
TDOC 5.31 |
HCAT 4.19 |
SDGR 3.45 |
EVH 1.67 |
ACCD 1.48 |
DH 1.04 |
NRC -2.02 |
DOCS -4.27 |
HSTM -4.83 |
VEEV -5.77 |
PGNY -9.38 |
GDRX -52.78 |
PRVA -153.67 |
Cash to Cap | 0.23 | 6/18 | AMWL 1.29 |
HCAT 0.99 |
TDOC 0.58 |
ACCD 0.33 |
TXG 0.28 |
GDRX 0.23 |
DH 0.23 |
TALK 0.18 |
PRVA 0.15 |
CERT 0.11 |
EVH 0.09 |
SDGR 0.09 |
HSTM 0.06 |
PGNY 0.05 |
VEEV 0.03 |
NXGN 0.03 |
NRC 0.01 |
DOCS 0.01 |
CCR | 10.08 | 2/18 | PRVA 10.79 |
GDRX 10.08 |
HSTM 5.87 |
PGNY 4.10 |
DOCS 1.59 |
NRC 1.38 |
SDGR 0.91 |
VEEV 0.88 |
AMWL 0.56 |
ACCD 0.06 |
DH -0.15 |
EVH -0.40 |
TXG -0.50 |
HCAT -0.83 |
TALK -1.28 |
NXGN -3.76 |
TDOC -5.07 |
CERT -18.58 |
EV to EBITDA | 110.90 | 6/18 | TALK} 5623.21 |
PRVA} 265.89 |
DOCS} 262.24 |
VEEV} 203.53 |
PGNY} 144.50 |
GDRX} 110.90 |
NXGN} 93.63 |
HSTM} 55.32 |
NRC} 47.67 |
AMWL} 1.49 |
DH} -4.29 |
SDGR} -24.80 |
ACCD} -25.69 |
TXG} -47.23 |
HCAT} -54.52 |
TDOC} -56.19 |
EVH} -203.17 |
CERT} -354.59 |
EV to Revenue | 1.87 | 9/18 | DOCS 26.96 |
VEEV 13.89 |
SDGR 8.78 |
CERT 6.10 |
HSTM 3.37 |
NRC 3.16 |
NXGN 2.63 |
TALK 2.04 |
GDRX 1.87 |
DH 1.87 |
TXG 1.78 |
PGNY 1.58 |
PRVA 1.45 |
HCAT 1.22 |
TDOC 0.96 |
ACCD 0.91 |
EVH 0.67 |
AMWL -0.18 |